The Long Noncoding RNA LOXL1-AS1 Promotes the Proliferation, Migration, and Invasion in Hepatocellular Carcinoma

Abstract

Objective. To investigate the expression of long noncoding RNA lysyl oxidase-like 1-antisense 1 (LOXL1-AS1) in hepatocellular carcinoma tissues and its effect on cell proliferation, migration, and invasion. Methods. Quantitative real-time PCR was used to analyze the expression of LOXL1-AS1 RNA in tumor tissues, adjacent normal tissues, and cell lines. MTT assay, colony formation assay, flow cytometry analysis, transwell assays, and lentivirus-mediated RNA interference (RNAi) technology were used to evaluate cell proliferation and migration. Results. In the present study, we observed that the expression level of LOXL1-AS1 in hepatocellular carcinoma tissue was significantly higher than that in adjacent nontumor tissues, and its expression in three hepatic carcinoma cell lines was obviously higher than that in a normal cell line. In addition, in the Hep-G2 cell line, LOXL1-AS1 downregulation significantly inhibited cell proliferation in the light of the MTT and colony formation assays in vitro, which was consistent with animal experiment in vivo. What is more, cell migration was also inhibited in vitro in Matrigel Transwell Assay by LOXL1-AS1 knockdown, which might be partly attributed to the reduction of MMP-2 and MMP-9 protein expressions. Finally, cell cycle analysis revealed that knockdown of LOXL1-AS1 induced significantly a G0/G1 phase cell cycle arrest, which might be partly attributed to the downregulation of Cdc2, Cdc25A, and cyclin B1 protein expression. Conclusion. In conclusion, we demonstrated that reduced LOXL1-AS1 expression could inhibit hepatocellular carcinoma cell proliferation, migration, and invasion. The application of RNAi targeting LOXL1-AS1 might be a potential treatment strategy in advanced cases.

lncRNA LOXL1‑AS1 promotes liver cancer cell proliferation and migration by regulating the miR‑377‑3p/NFIB axis

“…Previously, Liu et al (26) revealed that LOXL1-AS1 expression was upregulated in hepatocellular carcinoma tissues and promoted hepatocellular carcinoma cell proliferation, migration and invasion. In the present study, the current data confirmed the upregulation of LOXL1-AS1 expression in liver cancer tissues and cells, indicating that LOXL1 may act as an oncogene in liver cancer cellular processes.…”

Long non-coding RNA LOXL1-AS1: a potential biomarker and therapeutic target in human malignant tumors

“…Therefore, there is an urgent need for a reliable HCC progression biomarker to improve clinical strategy. Liu et al [ 34 ] reported that LOXL1-AS1 was generally increased in HCC tissues and cells, while downregulation of LOXL1-AS1 significantly inhibited cell proliferation, migration and invasion. Bioinformatics showed that miR-3614-5p could be absorbed by LOXL1-AS1 sponge, while Yin Yang 1 (YY1) was confirmed to be the target gene of miR-3614-5p, and YY1 deletion could inhibit the malignant behavior of HCC cells.…”

“…Using modern technology, we detect lncRNAs expression in clinical tissue samples, which makes LOXL1-AS1 to be used as a biomarker for cancer diagnosis. As mentioned above, LOXL1-AS1 is highly expressed in tissue samples from most types of cancer, including EC [ 17 ], CRC [ 22 ], GC [ 27 ], HCC [ 34 ], PCa [ 38 ], NSCLC [ 42 ], OC [ 47 ], CC [ 52 ], BC [ 55 ], gliama [ 59 ], OS [ 64 ], CCA [ 65 ], laryngocarcinoma [ 66 ], medulloblastoma [ 67 ], RB [ 68 ], RCC [ 69 ], ESCC [ 70 ], TC [ 71 ], PC [ 72 ]. In normal tissues, LOXL1-AS1 expression is limited.…”

LncRNA LOXL1-AS1 expression in cancer prognosis: A meta-analysis

“…Long et al [10] reported that LOXL1-AS1 is involved in the proliferation and cell cycle of prostate cancer. In addition, abnormally high expression of LOXL1-AS1 was found in a variety of tumors, such as osteosarcoma, [11] epithelial ovarian cancer, [12] gastric cancer, [13,14] thymic epithelial tumors, [15] endometrial cancer, [16] liver cancer, [17][18][19] cholangiocarcinoma [20] and cervical cancer. [21][22][23] And more notably, LOXL1-AS1 has been shown to have the potential as a prognostic biomarker in a variety of tumors.…”